Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CENTREXION THERAPEUTICS CORPORATION

(CNTX)
 SummaryQuotesNewsCompanyFinancials 
Estimated financial data (e) (USD)
Sales 2017 - - -
Net income 2017 -24,6 M - -
Net cash position 2017 58,7 M - -
P/E ratio 2017 -
Yield 2017 -
Sales 2018 - - -
Net income 2018 -39,0 M - -
Net cash position 2018 23,8 M - -
P/E ratio 2018 -
Yield 2018 -
Capitalization - - -
EV / Sales 2017 -
EV / Sales 2018 -
Nbr of Employees 24
Free-Float -
More Financials
Company
Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies... 
More about the company
All news about CENTREXION THERAPEUTICS CORPORATION
12/02Context Therapeutics Q3 Net Loss Widens
MT
12/02Management's discussion and analysis of financial condition and results of ..
AQ
12/02Earnings Flash (CNTX) CONTEXT THERAPEUTICS Reports Q3 Loss $-4.00
MT
12/02Context Therapeutics« Reports Third Quarter 2021 Operating and Financial Results
AQ
12/02Health Care Stocks Trailing Thursday Field Higher
MT
12/02Context Therapeutics Expects to Raise $31.3 Million in Private Placement of Common Shar..
MT
12/01Context Therapeutics Inc. Announces $31.25 Million Private Placement
AQ
11/19Context Therapeutics« to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San A..
GL
11/01Context Therapeutics Names Jennifer Minai-Azary Chief Financial Officer
MT
11/01CONTEXT THERAPEUTICS INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
11/01Context Therapeutics« Strengthens Leadership Team with Appointments of Chief Financial ..
AQ
10/22CONTEXT THERAPEUTICS INC. : Change in Directors or Principal Officers, Amendments to Artic..
AQ
10/22CENTREXION THERAPEUTICS : Context Therapeutics Closes $28.8 Million IPO
MT
10/22CENTREXION THERAPEUTICS : Context Therapeutics« Announces Closing of Initial Public Offeri..
AQ
10/20CENTREXION THERAPEUTICS : Context Therapeutics Debuts On Nasdaq
MT
More news
News in other languages on CENTREXION THERAPEUTICS CORPORATION
12/02La perte nette de Context Therapeutics au troisième trimestre s'accentue
12/02Les actions du secteur de la santé en hausse jeudi
12/02Context Therapeutics prévoit de lever 31,3 millions de dollars dans le cadre d'un place..
11/01Context Therapeutics nomme Jennifer Minai-Azary au poste de directeur financier.
10/22Context Therapeutics réalise une introduction en bourse de 28,8 millions de dollars.
More news
Chart CENTREXION THERAPEUTICS CORPORATION
Duration : Period :
Centrexion Therapeutics Corporation Technical Analysis Chart | CNTX | US15643W1009 | MarketScreener
Income Statement Evolution
Managers and Directors
Jeffrey B. Kindler Chief Executive Officer & Director
James N. Campbell President, Director & Chief Scientific Officer
Brian Nicholas Harvey Chief Financial Officer, Treasurer & Executive VP
Sol J. Barer Chairman
Randall M. Stevens Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CENTREXION THERAPEUTICS CORPORATION0.00%0
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-40.67%24 745